MYD88 and B-cell chronic lymphocytic leukemia: In contrast, for young or fit patients, only 39.47% considered BTKis universally preferred, with 57.89% reserving them for patients with poor prognostic biomarkers, such as del(17p) or unmutated IgHV in CLL, or MYD88 mutations in WM.